Cardiac and renal outcomes of direct oral anticoagulants in patients with atrial fibrillation
Article 2023 en
Authors
YW
Yuting Wang
JC
Jo‐Hsin Chen
SL
Shu‐Fen Liao
Abstract
1 min read
In this study, patients treated with dabigatran had significantly reduced risks of declining renal function and composite cardiac and renal events than those treated with warfarin. However, rivaroxaban and edoxaban were not associated with lower risks of any renal outcomes than warfarin. More studies are warranted to investigate and compare the impact of renal function between different DOACs in patients with AF.
Nour R. Al‐Hussainy, Kristian Kragholm, Søren Lundbye‐Christensen, Christian Torp‐Pedersen, Manan Pareek, Susette Krohn Therkelsen, Professor Gregory Lip, Sam Riahi
Discussion(0)
No comments yet. Be the first to comment.